No Data
No Data
Hong Kong stock concept tracking | WHO: Summer COVID-19 resurgence is not ruled out, inflow of funds into the biomedical sector (with concept stocks).
WHO: COVID-19 infection rate is soaring in summer, and the possibility of recurrence cannot be ruled out.
Some pharmaceutical stocks are rising against the market, and Beigene (06160) is up 5.03%. Institutions point to the pharmaceutical sector entering a value investment range.
Some pharmaceutical stocks bucked the trend, with BeiGene (06160) rising 5.03%, Shandong Xinhua Pharmaceutical (00719) rising 3.61%, Hansoh Pharma (03692) rising 2.38%, Joinn Laboratories (06127) rising 2.22%, and CanSinoBio (06185) rising 1.59%. News-wise, China International Capital Corporation released research reports stating that after 3 years of systematic adjustments, the pharmaceutical sector has entered the value investment range. Along with the gradual stabilization of domestic policies and the introduction of policies related to innovative drugs, the domestic innovative drug industry chain and overseas expansion are worth paying attention to in the second half of 2024.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Jenkem Technology (688356.SH): The three-component LNP developed in collaboration with Cansino Biologics Inc. can be licensed to other companies.
Jenkem Technology (688356.SH) stated on the investor interaction platform on July 16 that the three-component LNP developed in cooperation with Cansino Biologics Inc. can be licensed to other companies.
Cansinobio received shareholding of 0.02 million H shares from its controlling shareholder, Yu Xuefeng.
Cansinobio (06185) issued an announcement on July 9, 2024, stating that the company received notice from XUEFENG YU, one of its controlling shareholders and chairman and CEO, that he has increased his shareholding by 0.02 million H shares, accounting for 0.01% of the company's total share capital (as of July 9, 2024, the company's total share capital was 0.247 billion shares, including 0.133 billion H shares and 0.115 billion A shares). Prior to this shareholding increase, XUEFENG YU directly held 11.5902 million H shares, and after the increase, he directly holds 11.6102 million H shares.
Cansino Biologics Inc. (listed in Hong Kong Stock Exchange with ticker 688185.SH): Director and CEO Yu Xuefeng increases shareholding by 0.02 million H shares.
On July 11th, Gelunhui reported that Cansino Biologics Inc. (688185.SH) announced that on July 9th, 2024, it received notification from XUEFENG YU, one of its controlling shareholders and chairman and general manager, that he had increased his holdings of the company's H shares by 20,000 shares, accounting for approximately 0.01% of the company's total share capital (as of July 9th, 2024, the company's total share capital was 247,449,899 shares, of which 132,670,900 shares were H shares and 114,778,999 shares were A shares). Prior to this shareholding, XUEFENG YU directly held 11,590 shares of the company.
No Data